Phenazine compound for measuring bacterial efflux

EP4466254A1Pending Publication Date: 2024-11-27UNIV DAIX MARSEILLE +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2023701710
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-01-21
Filing Date
2023-01-23
Publication Date
2024-11-27

AI Technical Summary

Technical Problem

Current methods lack a standardized and reliable way to measure and quantify bacterial efflux, which is crucial for anticipating antibiotic resistance, as efflux mechanisms contribute to the emergence of multi-resistance phenotypes in bacteria, making infection treatment challenging.

Method used

Development of phenazinium compounds that are efficiently effluxed by bacteria via efflux pumps, allowing for the measurement of bacterial efflux and potential resistance, utilizing their fluorescent and coloring properties to visually and quantitatively assess efflux activity.

Benefits of technology

Enables effective visualization and quantification of efflux activity, distinguishing between different levels of efflux pump production, thereby aiding in the identification of antibiotic resistance potential without the need for specialized equipment, facilitating better treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1.1
    Figure 1.1
Patent Text Reader

Abstract

The invention relates to a compound of the following formula (I) in which X is an anion, in which R1 and R2 are either together -CH3 or a C1-C4 alkyl such that, if R1 is a Cn+1 alkyl, R2 is a Cn alkyl, and vice versa, n being an integer ranging from 1 to 3, i being an integer ranging from 1 to 3 and in which n+i ranges from 1 to 4; and in which R3 is a -CH3 or a C2-C8 alkyl, said C2-C8 alkyl being optionally substituted with one or more heteroatoms.
Need to check novelty before this filing date? Find Prior Art

Description

PHENAZINE COMPOUND FOR MEASURING BACTERIAL EFFUX

[0001] The invention relates to cyclic compounds, and in particular their use in the context of measuring bacterial efflux.

[0002] In biology, efflux is a mechanism by which cells release into the external environment compounds that are toxic to their metabolism, such as antibiotics, heavy metals, drugs, etc. Efflux is an active, energy-dependent transport mechanism, ensured by transmembrane proteins called efflux pumps.

[0003] In prokaryotes, and particularly bacteria, numerous efflux systems have been described, but these mechanisms can also be observed in eukaryotes.

[0004] Due to the expulsion of compounds into the external environment, the mechanisms responsible for efflux contribute, among other things, to the emergence of resistance to various pharmacological treatments such as antibiotic resistance or resistance to anticancer chemotherapy. The broad spectrum of certain efflux pumps observed in certain bacteria can lead to the appearance of multidrug resistance phenotypes, thus making the treatment of infections very difficult.

[0005] Therefore, there is a need to measure efflux in order to anticipate bacterial resistance.

[0006] One of the aims of the invention is to provide compounds and methods for measuring bacterial efflux.

[0007] Another aim of the invention is to propose a method for evaluating the antibiotic resistance of bacteria.

[0008] The invention relates to a compound of the following formula I: (I)

[0009] where X - is a halogen atom, or an acceptable counter ion, in particular Cl,

[0010] where R1 and R2 are

[0011] - either jointly -CH3, or -C4H9

[0012] - either a C1-C4 alkyl, such that if R1 is a Cn+i alkyl, R2 is a Cn alkyl, and vice versa, n being an integer varying from 1 to 3, i being an integer varying from 1 to 3 and or n+i varies from 1 to 4;

[0013] - either R1 is -C4H7 and R2 is C8H 17 , And

[0014] where R3 is -CH3, or C2-C8 alkyl, said C2-C8 alkyl being optionally substituted by one or more heteroatoms;

[0015] or a salt or solvate of this compound of formula I, or a protonated form thereof.

[0016] In other words, does the invention relate to a compound of formula I mentioned above?

[0017] X- is a halogen atom, or an acceptable counter ion, especially Cl,

[0018] where R1 and R2 are

[0019] - either jointly -CH3, or -C4H9,

[0020] - either a C1-C4 alkyl, such that

[0021] - if R1 is a Cn+i alkyl, R2 is a Cn alkyl,

[0022] - if R1 is a Cn alkyl, R2 is a Cn+i alkyl,

[0023] n being an integer varying from 1 to 3, i being an integer varying from 1 to 3 and where n+i varies from 2 to 4;

[0024] - either R1 is C4H9 and R2 is C8H 17 , And

[0025] where R3 is -CH3, or C2-C8 alkyl, said C2-C8 alkyl being optionally substituted by one or more heteroatoms;

[0026] or a salt or solvate of this compound of formula I, or a protonated form thereof.

[0027] Advantageously, the invention relates to a compound of the following formula I: (I)

[0028] where X -is a halogen atom, or an acceptable counter ion, in particular Cl,

[0029] where R1 and R2 are

[0030] - either jointly -CH3,

[0031] - either a C1-C4 alkyl, such that if R1 is a Cn+i alkyl, R2 is a Cn alkyl, and vice versa, n being an integer varying from 1 to 3, i being an integer varying from 1 to 3 and or n+i varies from 1 to 4; and

[0032] where R3 is -CH3, or C2-C8 alkyl, said C2-C8 alkyl being optionally substituted by one or more heteroatoms;

[0033] or a salt or solvate of this compound of formula I, or a protonated form thereof.

[0034] The invention is based on the surprising observation made by the inventors that the above-mentioned compounds of formula I are colored and fluorescent compounds which are efficiently effluxed by bacteria by means of the different efflux pumps, so that said compounds make it possible to measure bacterial efflux and to measure a potential resistance of said bacteria.

[0035] The compounds of formula I are phenaziniums, i.e., cationic protonated forms of phenazines. Alkyl forms of the phenaziniums of the invention are also contemplated.

[0036] In compounds of formula I, X -is an acceptable and in particular pharmaceutically acceptable counter-anion, that is to say a counter-anion whose use is compatible with animal or bacterial physiology. Advantageous counter-anions are in particular counter-anions where X is a halogen atom such as F, Cl, Br or I, the advantageous halogen being Cl. Other counter-ions are conceivable such as chlorates, bromates, hydrogen carbonates, acetates, butyrates, formates, tartrates, aluminates, salicylates, mesylates, boron anions, phosphorus anions such as in particular hexafluorophosphate (PF6 - ) or tetrafluoroborate (BF4 - ).

[0037] The compounds according to formula I are therefore phenaziniums where the groups R1, R2 and R3 are defined as follows:

[0038] - either R1 and R2 are groups - CH3, or -C4H9,

[0039] - either R1 and R2 are C1-C4 alkyls, i.e. C1, C2, C3 or C4 alkyls, preferably linear, such that R1 and R2 always have a carbon atom difference. This is defined by the phase specifying that if R1 is Cn alkyl, R2 is Cn+i alkyl, and if R1 is Cn+i alkyl, R2 is Cn alkyl, where i is an integer ranging from 1 to 3 and where n+i varies from 2 to 4,

[0040] - either R1 is -C4H7 and R2 is C8H 17 .

[0041] In other words, R1 and R2 are

[0042] - jointly a -CH3, or,

[0043] when R1 and R2 are linear C1-C4 alkyls,

[0044] - R1 = -CH3 and R2 = -C2H5 or R1 = -C2H5 and R2 = -CH3, or

[0045] - R1 = -C2H5 and R2 = -C3H7 or R1 = -C3H7 and R2 = -C2H5, or

[0046] - R1 = -C3H7 and R2 = -C4H9 or R1 = - C4H9 and R2 = -C3H7.

[0047] Obviously, when R1 or R3 are C3 alkyls, they can be -C3H7(ie -CH2-CH2-CH3) or -CH(CH3)2, and when they are C4 alkyls they can be -C4H9(ie -CH 2-CH2-CH2-CH3), -CH(CH3)-CH2-CH3ou -CH2-CH(CH3)2ou -C(CH3)3.

[0048] As for R3, this is a methyl (-CH3) or a C2-C8 alkyl, i.e. an alkyl:

[0049] - in C1, ie -CH3, or

[0050] - in C2, ie -C2H5(ie -CH2-CH3), or

[0051] - in C3, ie -C3H7(ie -CH2-CH2-CH3) or -CH(CH3)2, or

[0052] - in C4, ie -C4H9(ie -CH2-CH2-CH2-CH3), -CH(CH3)-CH2-CH3or -CH2-CH(CH3)2or -C(CH3)3, or

[0053] - in C5, ie -C5H11 (ie -CH2-CH2-CH2-CH2-CH3), -CH(CH3)-CH2-CH2-CH3, -CH2-CH(CH3)-CH2-CH3, - CH2-CH2-CH(CH3)2, -C(CH3)2-CH2-CH3, -CH(CH3)-CH(CH3)-CH 3, -CH2-C(CH3)3or -CH(CH3)-CH(CH3)2, or

[0054] - in C6, ie -C6H13 (ie -CH2-CH2-CH2-CH2-CH2-CH3), or a branched form, or

[0055] - in C7, ie -C7H15 (ie -CH2-CH2-CH2-CH2-CH2-CH2-CH3), or a branched form, or

[0056] - in C8, ie -C8H17 (ie -CH2-CH2--CH2CH2-CH2-CH2-CH2-CH3), or a branched form.

[0057] When R3 is a C2-C8 alkyl, each of the carbon atoms can be substituted by a heteroatom, that is to say by an oxygen (O), nitrogen (N) or sulfur (S) atom, or even phosphorus (P). For example, a C4 alkyl can have one of its carbons substituted by an oxygen, and we will obtain the following R3 residues:

[0058] - -O-CH2-CH2-CH3, or

[0059] - -CH2-O-CH2-CH3, or

[0060] - -CH2-CH2-O-CH3, or

[0061] - -CH2-CH2-NH-CH3, or even

[0062] - -CH2-CH2-CH2-OH.

[0063] These examples are illustrative and do not limit the scope of the invention.

[0064] The protonated forms of the above-mentioned compound of formula I are also covered by the present invention.

[0065] Advantageously, the invention relates to the compound as defined above, where R1 and R2 are each a C2-C4 alkyl, such that:

[0066] - if R1 is a Cn+1 alkyl, R2 is a Cn alkyl, or

[0067] - if R2 is a Cn+i alkyl, R1 is a Cn alkyl,

[0068] n varying from 1 to 3, i being an integer varying from 1 to 3 and or n+i varying from 1 to 4, and R3 is as defined below.

[0069] Advantageously, the invention relates to the compound as defined above, where R3 is a C2-C4 alkoxy group, in particular methoxyethyl, a dimethylamineethyl or methylaminexethyl group.

[0070] Even more advantageously, the invention relates to the above-mentioned compound, said compound being selected from the group of compounds of formula I, where R1, R2 and R3 are together as indicated in each row of the following table:

[0071] compoundR1R2R3methylmethylpropylmethylethylpropylethylmethylpropylethylpropylpropylpropylethylpropylpropylbutylpropylbutylpropylpropylmethylmethylbutylmethylethylbutylethylmethylbutylethylmethylbutylethylpropylbutylpropylethylbutylpropylbutylbutyl#47butylpropylbutylmethylmethylmethoxyethylmethylethylmethoxyethylethylmethylmethoxyethylethylpropylmethoxyethylpropylethylmethoxyethylpropylbutylmethoxyethyl#53butylpropylmethoxyethyl#52butylpropyloctyl#392 or #44butyloctylmethoxyethyl#29butylbutylpropyl

[0072] Note that compound #392 is also named #44

[0073] Even more advantageously, the invention relates to the above-mentioned compound, said compound being chosen from the compounds of formulas 47, 52, 53, 392 and 29 below: (47), (52), and (53), (392), and (29).

[0074] These three compounds are the most advantageous compounds of the invention and their synthesis is described in detail in Example 1, below.

[0075] Advantageously, the invention relates to the compound as defined above, as a medicament, or for its use as a medicament. Also envisaged is a use of the compound as defined above, for the manufacture of a medicament.

[0076] Also contemplated is a pharmaceutical composition comprising as active ingredient a compound as defined above, in association with a pharmaceutically acceptable vehicle. Preferably, the compound of formula (I) as defined above, or its pharmaceutically acceptable salt, is administered or administrable in a unit dose, or is packaged in a unit dose, of about 50 mg to about 1500 mg, in particular of about 150 to about 200 mg. Also preferably, the compound of formula (I) as defined above, or its pharmaceutically acceptable salt, is administered or administrable with a dosage regimen of 50 mg / day to about 1500 mg / day, in particular of about 150 mg / day to about 200 mg / day. Preferably, the compound of formula (I) as defined above, or its pharmaceutically acceptable salt, is administered or administrable in a form suitable for oral or injectable administration.More preferably, the compound of formula (I) as defined above, or its pharmaceutically acceptable salt, is administered or administrable in the form of a powder, tablets, capsules or sachets.

[0077] Even more advantageously, the above-mentioned compound or pharmaceutical composition is used in the treatment of, or for the treatment of, Gram-positive bacterial infections. The above-mentioned compound has antibacterial properties that may be useful in the treatment of infections.

[0078] More advantageously, the aforementioned compound is used in antibacterial therapies, to treat pathologies or infections related to contamination by Gram-positive bacteria that are not capable of effluating compounds, or bacteria that do not express or express few pumps responsible for antibiotic resistance.

[0079] In another aspect, the aforementioned compound, which has antibiotic, or at least antibacterial, properties, can be used in the decontamination of inert surfaces infected, or contaminated by bacteria. The compound is then brought into contact with the contaminated surface in order to kill and / or inhibit the growth of the contaminating bacteria. The compound can be used in the form of a powder to be spread on the surface to be decontaminated, or in the form of a solution which can be poured or sprayed onto the surface to be decontaminated.

[0080] It is also envisaged to use the above-mentioned compound, in order to stain or to carry out a colored or fluorescent marking, of Gram-positive bacteria, and more particularly Gram-positive bacteria which are not capable of effluxing compounds, that is to say bacteria which do not express or express few pumps responsible for multiple drug resistance (pumps allowing efflux).

[0081] The invention also relates to the use of a compound as defined above, for evaluating or measuring, that is to say for observing qualitatively or quantifying the efflux of said compound by a bacterium.

[0082] As illustrated in the examples, the compound according to the invention is capable of being expelled from bacteria by the efflux mechanism. Also, since the compound according to the invention is colored and / or fluorescent, it is easy to follow its efflux from the inside of the bacteria to the outside.

[0083] It is also possible to use the compound of the invention to identify whether or not a bacterial isolate overproduces its efflux pumps. Also, by measuring or evaluating the efflux of the compound of the invention, it is possible to determine whether a pump is overproduced or overexpressed, or on the contrary underproduced or underexpressed.

[0084] It is thus possible to measure characteristics such as the efflux speed, which can possibly provide information on the quantity of efflux pumps present on the bacterial membrane, or to measure the variation in activity (efflux capacity) of pumps following mutagenesis (induced or natural).

[0085] To the extent that the compound is colored and / or fluorescent, it will be possible to measure on the one hand the coloration / fluorescence at the start of the experiment when the compound comes into contact with the bacteria, and after a determined time, either the fluorescence or the color in the bacteria, or in the external environment.

[0086] More advantageously the invention relates to the aforementioned use, for evaluating or measuring efflux by Gram-positive bacteria.

[0087] Several genes encoding efflux systems have been described in Gram-positive bacteria. Their product forms a protein transporter that reduces the accumulation of the antibiotic in the cell.

[0088] For example, the genes msrA and msrB are responsible for an MS-type resistance phenotype, i.e., inducible resistance to macrolides with 14 and 15 carbons (C14 and C15) in the nucleus and to the B compound of streptogramins, after induction by erythromycin. The mef gene results in a resistance phenotype called M, characterized by limited resistance to C14 and C15 macrolides.

[0089] The vgaA, vgaB genes encode efflux proteins for the single compound A of synergistins. All these genes are found in different species of Staphylococcus aureus (SA) and coagulase-negative staphylococci (CNS).

[0090] These are only examples, and this list is in no way to be considered as limiting the invention.

[0091] More advantageously the invention relates to the aforementioned use, for evaluating or measuring efflux by Gram-negative bacteria.

[0092] Advantageously, the aforementioned use relates to the measurement or evaluation

[0093] In another aspect, the invention relates to a kit for detecting or measuring bacterial efflux, comprising

[0094] - a compound as defined above, and

[0095] - at least one control bacteria.

[0096] The kit of the invention therefore contains a compound according to the invention which is capable of being effluxed by bacteria, and in addition a control of the experiment, a control bacterium for which the efflux of said compound is known.

[0097] This control bacterium can express either a wild-type pump, the efflux of which is known in particular with precision and reproducibility, or a mutant pump which no longer allows efflux due to a lack of expression of the proteins forming the pump or a structural modification affecting the function. Other control bacteria can obviously be used and in an advantageous aspect it can be provided with the kit, or the kit, both a positive control (a bacterium with a functional efflux pump) and a negative control (a bacterium with a non-functional or absent efflux pump).

[0098] To the extent that the compound according to the invention is colored and / or fluorescent, it is also possible to include in the kit according to the invention color palettes making it possible to define whether or not a bacterium is capable of effluating a compound, or even means of detecting fluorescence.

[0099] Advantageously, the invention relates to the use of the kit as defined above, for measuring or quantifying the efflux of said compound by a bacterium, in particular a Gram-positive bacterium, in particular S. aureus, B. subtilis, and S. pneumoniae.

[0100] Advantageously, the invention relates to the use of the kit as defined above, for measuring or quantifying the efflux of said compound by a Gram-negative bacterium, in particular Escherichia coli.

[0101] Even more advantageously, the invention relates to the aforementioned kit, further comprising a protonophore, in particular chosen from 2,4-dinitrophenol, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), C4R1, Ellipticine, 10-[2-(3-hydroxy-6-oxo-xanthen-9-yl)benzoyl]oxydecyl-triphenyl-phosphonium bromide and 2-(2-Hydroxyaryl)hexylphosphonium bromide, and in particular CCCP.

[0102] In the measurement of efflux of Gram-negative bacteria, the use of a protonophore, especially CCCP, is particularly appropriate. The protonophore found in the above-mentioned kit is intended for use at concentrations ranging from 0.25 to 15µg.mL -1 This means that the protonophore can be used at any dose varying within this range and in particular at a dose of 0.25 µg.mL -1 , 0.5µg.mL -1 , 0.75µg.mL -1 , 1µg.mL -1, 1,25µg.mL -1 , 1,5µg.mL -1 , 1,75µg.mL -1 , 2µg.mL -1 , 2,25µg.mL -1 , 2,5µg.mL -1 , 2,75µg.mL -1 , 3µg.mL -1 , 3,25µg.mL -1 , 3,5µg.mL -1 , 3,75µg.mL -1 , 4µg.mL -1 , 4,25µg.mL -1 , 4,5µg.mL -1 , 4,75µg.mL -1 , 5µg.mL -1 , 5,25µg.mL -1 , 5,5µg.mL -1 , 5,75µg.mL -1 , 6µg.mL -1 , 6,25µg.mL -1 , 6,5µg.mL -1 , 6,75µg.mL -1 , 7µg.mL -1 , 7,25µg.mL -1 , 7,5µg.mL -1 , 7,75µg.mL -1 , 8µg.mL -1 , 8,25µg.mL -1 , 8,5µg.mL -1 , 8,75µg.mL -1 , 9µg.mL -1 , 9,25µg.mL -1 , 9,5µg.mL -1 , 9,75µg.mL -1 , 10µg.mL -1 , 10,25µg.mL -1 , 10,5µg.mL -1 , 10,75µg.mL -1 , 11µg.mL -1 , 11,25µg.mL -1 , 11,5µg.mL -1 , 11,75µg.mL -1, 12µg.mL -1 , 12.25µg.mL -1 , 12.5µg.mL -1 , 12.75µg.mL -1 , 13µg.mL -1 , 13.25µg.mL -1 , 13.5µg.mL -1 , 13.75µg.mL -1 , 14µg.mL -1 , 14.25µg.mL -1 , 14.5µg.mL -1 , 14.75µg.mL -1 or 15µg.mL -1 . A person skilled in the art will be able to determine the appropriate dose depending on the protonophore used. For example, it is advantageous, when using CCCP, to use a dose of 5 µg.mL. -1 In yet another aspect, the invention relates to the use of a compound as defined above, for evaluating the resistance of a bacterium to a bacteriostatic or bactericidal compound.

[0103] Since the compound according to the invention can be effluxed by bacterial pumps, it can therefore logically be used to evaluate the efficiency of bacterial efflux.

[0104] If it is established that the compound according to the invention is effluxed, this means that the efflux is functional and therefore that the bacteria will be able to eliminate antibiotics. It will therefore be concluded, without needing to measure resistance using an antibiotic, that the bacteria concerned are resistant to antibiotics by an efflux phenomenon.

[0105] Conversely, if the compound according to the invention is not effluxed, this means that the efflux pumps are not functional, and therefore that antibiotics will not be effluxed either. Also, in the same way as for resistance, it will be possible to easily determine, without using an antibiotic, that the bacteria are sensitive to said antibiotics due to a lack of efflux.

[0106] In yet another aspect, the invention relates to a method for assessing resistance, in particular resistance due to an efflux mechanism, of a bacterium to a bacteriostatic or bactericidal compound, comprising:

[0107] - the cultivation of bacteria in a suitable culture medium, to obtain a culture of bacteria,

[0108] - bringing the bacterial culture into contact with a aforementioned compound, to obtain a culture of treated bacteria,

[0109] - washing the treated bacterial culture, and precipitating the bacteria contained in the treated bacterial culture to obtain a bacterial pellet,

[0110] - observation of the coloration of the bacterial pellet, such as

[0111] - if the bacterial pellet has the color of a bacterial pellet from a culture of untreated bacteria, said bacterium is resistant to said bacteriostatic or bactericidal compound, and

[0112] - if the bacterial pellet has a color different from the color of a bacterial pellet from the culture of untreated bacteria, said bacterium is not resistant to said bacteriostatic or bactericidal compound.

[0113] Alternatively, the evaluation method may comprise a filtration step replacing the centrifugation step. In this variant, the bacterial culture is passed over a filter and the bacteria are deposited on the latter. The coloration of the solid deposit of bacteria present on the filter is then evaluated to determine whether said bacteria exhibit resistance, in particular due to an efflux mechanism, to a bacteriostatic or bactericidal compound. According to this embodiment, the invention thus relates to a method for evaluating the resistance, in particular resistance due to an efflux mechanism, of a bacterium to a bacteriostatic or bactericidal compound, comprising:

[0114] - the cultivation of bacteria in a suitable culture medium, to obtain a culture of bacteria,

[0115] - bringing the bacterial culture into contact with a aforementioned compound, to obtain a culture of treated bacteria,

[0116] - washing the treated bacterial culture, and filtering the bacteria contained in the treated bacterial culture to obtain a filtrate on the one hand and a deposit of bacteria on a filter on the other hand,

[0117] - observation of the coloration of the solid deposit on the filter, such as

[0118] - if the solid deposit on the filter has the same color as a solid deposit from a culture of untreated bacteria, said bacteria is resistant to said bacteriostatic or bactericidal compound, and

[0119] - if the solid deposit has a color different from the color of a solid deposit from the culture of untreated bacteria, said bacterium is not resistant to said bacteriostatic or bactericidal compound.

[0120] Advantageously, the invention relates to a method for evaluating resistance due to an efflux mechanism of a bacterium to a bacteriostatic or bactericidal compound, comprising:

[0121] - the cultivation of bacteria in a suitable culture medium, to obtain a culture of bacteria,

[0122] - bringing the culture of bacteria into contact with a compound as defined above, to obtain a culture of treated bacteria,

[0123] - washing the treated bacterial culture, and precipitating the bacteria contained in the treated bacterial culture to obtain a bacterial pellet,

[0124] - observation of the coloration of the bacterial pellet, such as

[0125] - if the pellet of bacteria has the color of a pellet of bacteria from the culture of untreated bacteria, said bacterium is resistant to said bacteriostatic or bactericidal compound, by efflux of said bacteriostatic or bactericidal compound, and

[0126] - if the bacterial pellet has a color different from the color of a bacterial pellet from the culture of untreated bacteria, said bacterium is not resistant to said bacteriostatic or bactericidal compound by efflux of said bacteriostatic or bactericidal compound.

[0127] Even more advantageously, the invention relates to the aforementioned method, said method further comprising a step of incubating the culture of bacteria with a protonophore.

[0128] This means that advantageously the invention relates to a method for evaluating resistance due to an efflux mechanism of a bacterium to a bacteriostatic or bactericidal compound, comprising:

[0129] - the cultivation of bacteria in a suitable culture medium, to obtain a culture of bacteria,

[0130] - bringing the bacterial culture into contact with a protonophore, in particular a protonophore mentioned above, to obtain a pretreated bacterial culture,

[0131] - bringing the pretreated bacterial culture into contact with a compound as defined above, to obtain a treated bacterial culture,

[0132] - washing the treated bacterial culture, and precipitating the bacteria contained in the treated bacterial culture to obtain a bacterial pellet,

[0133] - observation of the coloration of the bacterial pellet, such as

[0134] - if the bacterial pellet has the color of a bacterial pellet from a culture of untreated bacteria, said bacterium is resistant to said bacteriostatic or bactericidal compound, by efflux of said bacteriostatic or bactericidal compound, and

[0135] - if the bacterial pellet has a color different from the color of a bacterial pellet from the culture of untreated bacteria, said bacterium is not resistant to said bacteriostatic or bactericidal compound by efflux of said bacteriostatic or bactericidal compound.

[0136] This method with pretreatment is particularly advantageous in the measurement of efflux of Gram-negative bacteria. The above-mentioned compound is very simple and is based on the color properties of the compounds according to the invention.

[0137] By incubating bacteria with the compound according to the invention, the latter will accumulate in the bacteria.

[0138] If the efflux pumps are functional, the compound will be effluvated and released into the medium. The bacteria will no longer have any compounds and the bacterial pellet from the culture will have the color of a pellet that has not been treated with the colored compound.

[0139] Conversely, if the efflux pumps are not functional, the compound will accumulate in the bacteria, and the pellet will then take on a color which will be that (with a variation in intensity) of the colored compound.

[0140] Also, by a simple colorimetric test it is possible, after washing to eliminate residual compounds which have been effluxed, or which have not been incorporated into the bacteria, to determine whether a bacterium is capable of carrying out an efflux of compounds, and therefore whether or not it will be resistant to antibiotics.

[0141] Colorimetric tests can be carried out using techniques known to those skilled in the art, and in particular according to the CIE 1976 L*a*b* color space. This is a color space particularly used for the characterization of surface colors. Three quantities characterize the colors: the lightness L* derives from the luminance of the surface; the two parameters a* and b* express the deviation of the color from that of a gray surface of the same lightness. Brief description of the figures

[0142] The invention will be better understood on reading the following description, given solely by way of example and with reference to the appended drawings in which:

[0143] is a representative photograph of a test of NorA efflux pump activity in Staphylococcus aureus strains using compound 053 at a concentration of 0.75 µg.mL -1Pellet A represents a pellet of strain CIP 76.26, a reference strain with normal efflux activity – the pellet is pale pink. Pellet B represents a pellet of strain SA 1199, a clinical strain with mild to moderate efflux activity – the pellet is orange. Pellet C represents a pellet of strain SA 1199 B, which corresponds to a mutant strain with high efflux activity – the pellet is white / off-white. Pellet D represents a pellet of strain SA K1758, a mutant strain lacking an efflux pump – the pellet is a bright dark pink.

[0144] is a graph showing fluorescence intensity as a function of wavelength (in nm) for: A: buffer, B: strain SA K1758, C: strain CIP 76.26, D: strain SA 1199 B and E: strain SA K1758.

[0145] is a histogram representing in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for: A: the buffer, B: the SA K1758 strain, C: the CIP 76.26 strain, D: the SA 1199 B strain and E: the SA K1758 strain.

[0146] represents a representative photo of a test using compound 053 at a concentration of 0.75 µg.mL -1 on mutants of the BmrA efflux pump from Bacillus subtilis. Pellet A represents a pellet of a wild-type BmrA strain – the pellet is pale pink. Pellet B represents a pellet of a BmrA-overexpressing strain – the pellet is white. Pellet C represents a pellet of bacteria with a BmrA deletion (BmrA∆) – the pellet is dark pink.

[0147] is a graph showing fluorescence intensity as a function of wavelength (in nm) for: A: buffer, B: B. subtilis strain overexpressing BrmA, C: wild-type B. subtilis strain, and D: BrmA ∆ strain.

[0148] is a histogram representing in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for: A: the buffer, B: the B. subtilis strain overexpressing BrmA, C: the wild-type B. subtilis strain and D: the BrmA ∆ strain.

[0149] is a histogram showing the fluorescence intensity measured by flow cytometry for different strains of Staphylococcus aureus treated with compound 053. A: a wild-type strain corresponding to CIP 76.25, B: a reference strain corresponding to the SA strain, C: a NorA-overproducing strain corresponding to SA1199B, and D: a NorA-deleted strain corresponding to SA K1758. ns: nonspecific. * indicates a significant difference with a p-value less than 0.05; **** = indicates a significant difference with a p-value less than 0.001 – One-way ANOVA test with Tukey test).

[0150] is a histogram showing the relative fluorescence intensity (in arbitrary units) for each Staphylococcus aureus strain treated with compound 053 and fixed with PFA or ethanol. A: wild-type strain corresponding to CIP 76.25 fixed with PFA, B: reference strain corresponding to strain SA fixed with PFA, C: NorA-overproducing strain corresponding to SA1199B fixed with PFA, D: NorA-deleted strain corresponding to SA K1758 fixed with PFA, E: wild-type strain corresponding to CIP 76.25 fixed with ethanol, F: reference strain corresponding to strain SA fixed with ethanol, G: NorA-overproducing strain corresponding to SA1199B fixed with ethanol, and H: NorA-deleted strain corresponding to SA K1758 fixed with ethanol.

[0151] represents a representative photo of a test using compound 053 at a concentration of 1µg.ml -1on mutants of the PatA-PatB transporter of Streptococcus pneumoniae. Pellet “9A” represents a pellet of a wild-type PatA-PatB strain. Pellet “9B” represents a pellet of a strain overexpressing PatA / PatB. Pellet “9C” represents a pellet of a strain with a PatA / PatB deletion.

[0152] is a histogram representing in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for different strains of Streptococcus pneumoniae. A: wild-type PatA-PatB strain, B: strain overexpressing PatA / PatB, C: strain with a deletion of PatA / PatB.

[0153] This is a representative photograph of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 392 at a concentration of 1 µg.mL -1Pellet "A" represents a pellet of strain ATCC 11775, a reference strain with normal efflux activity. Pellet "B" represents a pellet of wild-type strain (AG100) with normal efflux activity. Pellet "C" represents a pellet of strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. Pellet "C" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0154] Figure 1 represents a representative graph of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 392 at a concentration of 1 µg.mL -1This graph shows fluorescence intensity as a function of wavelength (in nm). “A” represents strain ATCC 11775, a reference strain with normal efflux activity. “B” represents the wild-type strain (AG100) with normal efflux activity. “C” represents strain AG100A, a mutant strain with a deletion of the AcrAB efflux pump. “D” represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0155] is a representative histogram of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 392 at a concentration of 1 µg.mL -1. It represents in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for different strains of Escherichia coli.). "A" represents strain ATCC 11775, a reference strain with normal efflux activity. "B" represents the wild-type strain (AG100) with normal efflux activity. "C" represents strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. "D" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0156] This is a representative photograph of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 029 at a concentration of 1 µg.mL -1Pellet "A" represents a pellet of strain ATCC 11775, a reference strain with normal efflux activity. Pellet "B" represents a pellet of wild-type strain (AG100) with normal efflux activity. Pellet "C" represents a pellet of strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. Pellet "D" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0157] Figure 1 represents a representative graph of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 029 at a concentration of 1 µg.mL. -1This graph shows fluorescence intensity as a function of wavelength (in nm). “A” represents strain ATCC 11775, a reference strain with normal efflux activity. “B” represents the wild-type strain (AG100) with normal efflux activity. “C” represents strain AG100A, a mutant strain with a deletion of the AcrAB efflux pump. “D” represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0158] is a representative histogram of an assay for AcrAB efflux pump activity in Escherichia coli strains using compound 029 at a concentration of 1 µg.mL -1. It represents in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for different strains of Escherichia coli.). "A" represents strain ATCC 11775, a reference strain with normal efflux activity. "B" represents the wild-type strain (AG100) with normal efflux activity. "C" represents strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. "D" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0159] This is a representative photograph of an assay for AcrAB efflux pump activity in Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP)-pretreated Escherichia coli strains using compound 053 at a concentration of 1 µg.mL -1Pellet "A" represents a pellet of strain ATCC 11775, a reference strain with normal efflux activity. Pellet "B" represents a pellet of wild-type strain (AG100) with normal efflux activity. Pellet "C" represents a pellet of strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. Pellet "D" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0160] represents a representative graph of an assay for AcrAB efflux pump activity in Escherichia coli strains pre-treated with Carbonyl Cyanide m-Chlorophenylhydrazone using compound 053 at a concentration of 1 µg.mL -1This graph shows fluorescence intensity as a function of wavelength (in nm). “A” represents strain ATCC 11775, a reference strain with normal efflux activity. “B” represents the wild-type strain (AG100) with normal efflux activity. “C” represents strain AG100A, a mutant strain with a deletion of the AcrAB efflux pump. “D” represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB.

[0161] is a representative histogram of an assay for AcrAB efflux pump activity in Escherichia coli strains pre-treated with Carbonyl Cyanide m-Chlorophenylhydrazone using compound 053 at a concentration of 1 µg.mL -1. It represents in the form of bars the maximum fluorescence emission values ​​at 642 nm (after excitation at a wavelength of 530 nm) for different strains of Escherichia coli.). "A" represents strain ATCC 11775, a reference strain with normal efflux activity. "B" represents the wild-type strain (AG100) with normal efflux activity. "C" represents strain AG100A corresponding to a mutant strain deleted of the AcrAB efflux pump. "D" represents a pellet of strain AG102, a mutant strain with overexpression of AcrAB. Examples Example 1 – Syntheses

[0162] 1- Generic scheme for the synthesis of compounds according to the invention

[0163] The synthesis scheme for the various compounds of the invention is given below. Concerning three specific compounds, the details of the synthesis including intermediate steps are also detailed below. 2- Synthesis of compound 053 2a - step 1

[0164]

[0165] To a stirred solution of 1,4-dinitrofluorobenzene (DFNB - 2 mL, 2.9 g, 18.23 mmol, 1 eq.) in dichloromethane (DCM - 50 mL) at 0 °C, propylamine (1.5 mL, 1.08 g, 18.23 mmol, 1 eq.) was added, followed by the addition of N,N-diisopropylethylamine (DIPEA - 3.49 mL, 2.6 g, 20 mmol, 1.1 eq.). The reaction mixture was allowed to warm to room temperature (over 30 min), after which the reaction was complete (monitored by thin-layer chromatography (TLC)). The solvent was evaporated in vacuo to give a yellow residue which was purified by SiO2 gel column chromatography to give the desired product FBP-002 as a yellow oil (2.74 g, 13.8 mmol, 76%).

[0166] 1H-RMN(400 MHz ; CDCl3): δ 8,16 (m, 2H), 6,46 (dd,J1= 11,6 Hz,J2= 2,4 Hz, 1H), 6,34 (ddd,J1= 9,6 Hz,J2= 4,8 Hz,J3= 2,4 Hz, 1H), 3,21 (td,J1= 7 Hz,J2= 5,2 Hz, 2H), 1,75 (sext,J= 7,3 Hz, 2H), 1,05 (t,J= 7,4 Hz, 3H), 13 C-RMN(101 MHz ; CDCl3): δ 167,7 (d,J C-F = 257 Hz), 147,7 (d,J C-F = 14 Hz), 130,1 (d,J C-F = 13 Hz), 128,8, 103,9 (d,J C-F = 25 Hz), 99,3 (d,J C-F = 27 Hz), 45,1, 22,1, 11,6. 2b -étape 2

[0167]

[0168] To a solution of FBP-002 (3 g, 15 mmol, 1.0 eq.) in tetrahydrofuran (THF - 40 mL) was added butylamine (3.32 g, 4.48 mL, 45 mmol, 3 eq.) and DIPEA (3.3 g, 4.3 mL, 25.5 mmol, 1.7 eq.). The reaction mixture was stirred at 60 °C overnight. Then the solvent was evaporated and the residue was taken up in ethyl acetate (EtOAc - 150 mL), washed with saturated aqueous ammonium chloride solution (2 x 150 mL) and brine (100 mL). The combined organic layers were then dried over MgSO4, filtered and evaporated in vacuo. The obtained crude was purified by SiO2 gel column chromatography to obtain the desired product FBP-043 as an orange oil. (1.2 g, 4.8 mmol, 32% yield).

[0169] 1 H-NMR (400 MHz; CDCl3): δ 8.16 (m, 2H), 6.46 (dd,J1= 11.6 Hz,J2= 2.4 Hz, 1H), 6.34 (ddd,J1= 9.6 Hz,J2= 4.8 Hz,J3= 2.4 Hz, 1H), 3.21 (td,J1= 7 Hz,J2= 5.2 Hz, 2H), 1.75 (sext,J= 7.3 Hz, 2H), 1.05 (t,J= 7.4 Hz, 3H),13 C-NMR (101 MHz; CDCl3): δ 167.7 (d, J C-F = 257 Hz), 147.7 (d,J C-F = 14 Hz), 130.1 (d,J C-F = 13 Hz), 128.8, 103.9 (d,J C-F = 25 Hz), 99.3 (d,J C-F = 27 Hz), 45.1, 22.1, 11.6. 2c -stage 3

[0170]

[0171] A solution of FBP-043 (1.174 g, 4.67 mmol, 1 eq.) in THF (70 mL) was hydrogenated (P = 20 bar) in the presence of Pd / C (5%, 100 mg, 1.0 mol%) overnight. After reducing the pressure, the solution was degassed by bubbling Argon through the mixture. 1,5-Difluoro-2,4-dinitrobenzene (905 mg, 4.4 mmol, 0.95 eq.) was added at 0 °C with stirring. Maintaining this condition for 20 min, the completion of the reaction was detected by TLC (DCM / CH, 70 / 30). The Pd / C was then removed by filtration through a plug of Celite®. The crude product was purified by silica gel column chromatography (DCM / EP, 50 / 50) to give the desired product FB-005 as a deep reddish solid (1.466 g, 3.62 mmol, 77% yield).

[0172] 1H-RMN(400 MHz ; CDCl3): δ 9,30 (br, 1H), 9,14 (d,J= 8 Hz, 1H), 6,82 (d,J= 8,4 Hz, 1H), 6,53 (d,J= 13,6 Hz, 1H), 5,99 (dd,J1= 8,4 Hz,J2= 2,4 Hz, 1H), 5,95 (d,J= 2,4 Hz, 1H), 3,75 (br, 1H), 3,69 (br, 1H), 3,13 (t,J= 6 Hz, 2H), 3,06 (q,J= 6,4 Hz, 1H), 1,67-1,51 (m, 4H), 1,46 (sext,J= 7,4 Hz, 2H), 0,97 (t,J= 7,4 Hz, 3H), 0,92 (t,J= 7,4 Hz, 3H), 13 C RMN(101 MHz ; CDCl3): δ 159,9 (d,J C-F = 271 Hz), 150,5 (d,J C-F = 13 Hz), 150,3, 145,2, 128,7, 127,8, 126,9, 110,8, 103,9 (d,J C-F = 27 Hz), 101,7, 95,2, 45,3, 43,6, 43,2, 31,7, 22,6, 20,4, 14,0, 11,7. 1d -étape 4

[0173]

[0174] To a stirred solution of FB-045 (343 mg, 0.85 mmol, 1 eq.) in acetonitrile (15 mL) was added methoxyethylamine (221 µL, 191 mg, 2.54 mmol, 3 eq.). The mixture was stirred at room temperature for 2 hours, when completion was monitored by TLC. After evaporation of the solvent, hot ethanol (10 mL) was added to the crude residue. A resulting asphalt-like material was collected by filtration and washed with hot water (30 mL), then recovered by dissolution in dichloromethane, dried over anhydrous MgSO4, and filtered. After removal of the solvent under reduced pressure and drying of the solid in vacuo, the desired product FBP-051 was isolated as a dark asphalt-like solid (383 mg; 0.83 mmol; 98%).

[0175] 1H-RMN(400 MHz ; CDCl3): δ 9,26 (s, 1H), 9,13 (br, 1H), 8,36 (t,J= 4,6 Hz, 1H), 6,86 (d,J= 8 Hz, 1H), 5,99 (dd,J1= 8,4 Hz,J2= 2,4 Hz, 1H), 5,95 (d,J= 2,4 Hz, 1H), 5,71 (s, 1H), 3,79 (br, 1H), 3,67 (br, 1H), 3,54 (t,J= 5,4 Hz, 2H), 3,35 (s, 3H), 3,19-3,10 (m, 4H), 3,06 (t,J= 7 Hz, 2H), 1,67-1,51 (m, 4H), 1,45 (sext,J= 7,4 Hz, 2H), 0,97 (t,J= 7,4 Hz, 3H), 0,91 (t,J= 7,4 Hz, 3H), 13 C RMN(101 MHz ; CDCl3): δ 149,7, 149,3, 148,6, 145,4, 129,5, 128,8, 125,2, 124,5, 112,1, 101,6, 95,4, 93,2, 69,6, 59,1, 45,4, 43,8, 42,9, 31,8, 22,7, 20,4, 14,0, 11,7. 2e -étape 5

[0176]

[0177] A solution of compound FBP-051 (433 mg, 0.94 mmol, 1 equiv.) in methanol (20 mL) was hydrogenated (20 bar) in the presence of Pd / C (5 wt%, 36 mg) and HCl (12M, 0.30 mL) for 6 h. The mixture was then stirred under air for 16 h. The Pd / C was removed by filtration through a plug of Celite® which was rinsed several times with methanol and dichloromethane. After removal of the solvent under reduced pressure, the resulting solid was taken up with dichloromethane (50 mL), and extracted with brine (2 x 50 mL), the organic layer was then dried over MgSO4, filtered and evaporated in vacuo to give a crude black solid which was then purified on alumina oxide gel chromatography column (DCM / MeOH) and led to a deep purple solid of compound FBP-053 or compound 053 (177 mg, 0.44 mmol, 49% yield).

[0178] 1H-NMR (400 MHz; CD3OD): δ 7.68 (d,J= 9.2 Hz, 1H), 7.17 (dd,J1= 9.2 Hz,J2= 1.6 Hz, 1H), 6.94 (d,J= 1.6 Hz, 1H), 6.78 (s, 1H), 6.52 (br, 1H), 4.52 (t,J= 8 Hz, 2H), 3.73 (t,J= 5.2 Hz, 2H), 3.45 (t,J= 5.2 Hz, 2H), 3.42 (s, 3H), 3.32 (t,J= 7.2 Hz, 2H), 3.29 (sext,J= 1.6 Hz, 2H), 1.96 (sext,J= 7.6 Hz, 2H), 1.71 (quint,J= 7 Hz, 2H), 1.51 (sext,J= 7 Hz, 2H), 1.19 (t,J= 7.4 Hz, 3H), 1.01 (t,J= 7.4 Hz, 3H), 13 C NMR (101 MHz; CD3OD): δ 150.9, 139.2, 138.4, 135.5, 132.9, 131.4, 130.9, 92.4, 69.9, 57.8, 43.3, 42.7, 30.5, 20.1, 19.7, 12.9, 10.1; 5 masked or overlapping signals. High-resolution mass spectrometry: calculated for C 22 H 32 N5O + : 382.2601; obtained: 382.2593 3- synthesis of compound 052 3a - step 1

[0179]

[0180] To a stirred solution of DFNB (2 mL, 2.9 g, 18.23 mmol, 1 eq.) in DCM (50 mL) at 0 °C was added propylamine (1.5 mL, 1.08 g, 18.23 mmol, 1 eq.), followed by the addition of DIPEA (3.49 mL, 2.6 g, 20 mmol, 1.1 eq.). The reaction mixture was allowed to warm to room temperature (over 30 min), after which the reaction was complete (monitored by TLC). The solvent was evaporated in vacuo to give a yellow residue which was purified by SiO2 gel column chromatography to give the desired product FBP-002 as a yellow oil (2.74 g, 13.8 mmol, 76%).

[0181] 1 H-NMR (400 MHz; CDCl3): δ 8.16 (m, 2H), 6.46 (dd,J1= 11.6 Hz,J2= 2.4 Hz, 1H), 6.34 (ddd,J1= 9.6 Hz,J2= 4.8 Hz,J3= 2.4 Hz, 1H), 3.21 (td,J1= 7 Hz,J2= 5.2 Hz, 2H), 1.75 (sext,J= 7.3 Hz, 2H), 1.05 (t,J= 7.4 Hz, 3H).

[0182] 13 C NMR (101 MHz; CDCl3): δ 167.7 (d,J C-F = 257 Hz), 147.7 (d,J C-F = 14 Hz), 130.1 (d,J C-F= 13 Hz), 128.8, 103.9 (d,J C-F = 25 Hz), 99.3 (d,J C-F = 27 Hz), 45.1, 22.1, 11.6. 3b - step 2

[0183]

[0184] To a solution of FBP-002 (3 g, 15 mmol, 1.0 eq.) in THF (40 mL) was added butylamine (3.32 g, 4.48 mL, 45 mmol, 3 eq.) and DIPEA (3.3 g, 4.3 mL, 25.5 mmol, 1.7 eq.). The reaction mixture was stirred at 60 °C overnight. Then the solvent was evaporated and the residue was taken up in EtOAc (150 mL), washed with saturated aqueous ammonium chloride solution (2 x 150 mL) and brine (100 mL). The combined organic layers were then dried over MgSO4, filtered and evaporated in vacuo. The crude product obtained was purified by gel chromatography on a SiO2 column to obtain the desired product FBP-043 as an orange oil. (1.2 g, 4.8 mmol, 32% yield).

[0185] 1H-RMN(400 MHz ; CDCl3): δ 8,52 (br, 1H), 7,99 (d,J= 9,2 Hz, 1H), 5,89 (d,J= 9,6 Hz, 1H), 5,61 (s, 1H), 4,41 (br, 1H), 3,18 (m, 4H), 1,75 (sext,J= 7,2 Hz, 2H), 1,62 (quint,J= 7,2 Hz, 2H), 1,43 (sext,J= 7,5 Hz, 2H), 1,04 (t,J= 7,4 Hz, 3H), 0,96 (t,J= 7,2 Hz, 3H).

[0186] 13 CRMN(101 MHz ; CDCl3): δ 154,5, 148,7, 129,3, 123,7, 104,8, 90,0, 44,8, 43,0, 31,3, 22,2, 20,3, 13,9, 11,8. 3c -étape 3

[0187]

[0188] A solution of FBP-043 (1.174 g, 4.67 mmol, 1 eq.) in THF (70 mL) was hydrogenated (P = 20 bar) in the presence of Pd / C (5%, 100 mg, 1.0 mol%) overnight. After reducing the pressure, the solution was degassed by bubbling Ar into the mixture. 1,5-Difluoro-2,4-dinitrobenzene (905 mg, 4.4 mmol, 0.95 eq.) was added at 0 °C with stirring. Maintaining this condition for 20 min, the completion of the reaction was detected by TLC (DCM / CH, 70 / 30). The Pd / C was then removed by filtration through a plug of Celite®. The crude product was purified by silica gel column chromatography (DCM / EP, 50 / 50) to give the desired product FB-045 as a deep reddish solid (1.466 g, 3.62 mmol, 77% yield).

[0189] 1H-RMN(400 MHz ; CDCl3): δ 9,30 (br, 1H), 9,14 (d,J= 8 Hz, 1H), 6,82 (d,J= 8,4 Hz, 1H), 6,53 (d,J= 13,6 Hz, 1H), 5,99 (dd,J1= 8,4 Hz,J2= 2,4 Hz, 1H), 5,95 (d,J= 2,4 Hz, 1H), 3,75 (br, 1H), 3,69 (br, 1H), 3,13 (t,J= 6 Hz, 2H), 3,06 (q,J= 6,4 Hz, 1H), 1,67-1,51 (m, 4H), 1,46 (sext,J= 7,4 Hz, 2H), 0,97 (t,J= 7,4 Hz, 3H), 0,92 (t,J= 7,4 Hz, 3H).

[0190] 13 C RMN(101 MHz ; CDCl3): δ 159,9 (d,J C-F = 271 Hz), 150,5 (d,J C-F = 13 Hz), 150,3, 145,2, 128,7, 127,8, 126,9, 110,8, 103,9 (d,J C-F = 27 Hz), 101,7, 95,2, 45,3, 43,6, 43,2, 31,7, 22,6, 20,4, 14,0, 11,7. 3d -étape 4

[0191]

[0192] To a stirred solution of FB-045 (327 mg, 0.81 mmol, 1 eq.) in acetonitrile (15 mL) was added octylamine (398 µL, 311 mg, 2.41 mmol, 3 eq.). The mixture was stirred at room temperature for 2 hours, when completion was monitored by TLC. After evaporation of the solvent, hot ethanol (10 mL) was added to the crude residue. A resulting asphalt-like material was collected by filtration and washed with hot water (30 mL), then recovered by dissolution in dichloromethane, dried over anhydrous MgSO4, and filtered. After removal of the solvent under reduced pressure and drying of the solid in vacuo, the desired product FBP-050 was isolated as a dark solid (392 mg, 0.76 mmol, 94% yield).

[0193] 1H-RMN(400 MHz ; CDCl3): δ 9,26 (s, 1H), 9,12 (s, 1H), 8,20 (t,J= 5 Hz, 1H), 6,86 (d,J= 8,4 Hz, 1H), 5,99 (dd,J1= 8,2 Hz,J2= 2,4 Hz, 1H), 5,95 (d,J= 2,4 Hz, 1H), 5,69 (s, 1H), 3,79 (t,J= 5 Hz, 1H), 3,65 (br, 1H), 3,13 (t,J= 7 Hz, 2H), 3,06 (q,J= 6,3 Hz, 2H), 2,99 (q,J= 6,3 Hz, 2H), 1,97-1,50 (m, 8H), 1,45 (sext,J= 8 Hz, 2H), 1,30 (m, 8H), 0,97 (t,J= 7,2 Hz, 3H), 0,91 (t,J= 7,4 Hz, 3H), 0,87 (t,J= 7,4 Hz, 3H).

[0194] 13 C RMN(101 MHz ; CDCl3): δ 149,7, 149,2, 148,6, 129,6, 128,8, 125,0, 124,5, 112,1, 101,6, 95,3, 93,1, 45,4, 43,9, 43,2, 31,9, 31,8, 29,3, 29,2, 28,4, 27,0, 22,7, 22,6, 20,4, 14,2, 14,0, 13,9, 11,7. 3e -étape 5

[0195]

[0196] A solution of compound FBP-050 (316 mg, 0.61 mmol, 1 equiv.) in methanol (20 mL) was hydrogenated (20 bar) in the presence of Pd / C (5 wt%, 24 mg) and HCl (12M, 0.25 mL) for 6 h. The mixture was then stirred under air for 16 h. The Pd / C was removed by filtration through a plug of Celite® which was rinsed several times with methanol and dichloromethane. After removal of the solvent under reduced pressure, the resulting solid was taken up with dichloromethane (50 mL), and extracted with brine (2 x 50 mL), the organic layer was then dried over MgSO4, filtered and evaporated in vacuo to give a crude black solid which was then purified on alumina oxide gel chromatography column (DCM / MeOH) and led to a deep purple solid, compound FBP-052 or compound 052 (129 mg, 0.27 mmol, 45% yield).

[0197] 1H-NMR (400 MHz; CD3OD): δ 7.72 (d,J= 9.6 Hz, 1H), 7.18 (dd,J1= 9.2 Hz,J2= 2 Hz, 1H), 6.96 (s, 1H), 6.75 (s, 1H), 6.56 (br, 1H), 4.55 (t,J= 8.2 Hz, 2H), 3.32 (m, 2H), 3.28 (quint,J= 1.6 Hz, 2H), 3.25 (t,J= 7.4 Hz, 2H), 1.98 (sext,J= 8 Hz, 2H), 1.80-1.66 (m, 4H), 1.49 (quint,J= 8 Hz, 4H), 1.41-1.26 (m, 8H), 1.20 (t,J= 7.4 Hz, 3H), 1.01 (t,J= 7.4 Hz, 3H), 0.88 (t,J= 7.4 Hz, 3H).

[0198] 13 CRMN(101 MHz; CDCl3): δ 153.3, 150.9, 139.2, 138.6, 135.4, 131.3, 130.9, 102.8, 92.4, 48.9, 43.7, 42.7, 31.7, 30.5, 29.3, 29.1, 28.1, 27.1, 22.4, 20.1, 19.7, 13.1, 12.9, 10.1. 3 signals are masked or overlapping. 4- synthesis of compound 047 4a - step 1

[0199]

[0200] To a stirred solution of 1,4-dinitrofluorobenzene (DFNB - 2 mL, 2.9 g, 18.23 mmol, 1 eq.) in dichloromethane (DCM - 50 mL) at 0 °C, propylamine (1.5 mL, 1.08 g, 18.23 mmol, 1 eq.) was added, followed by the addition of N,N-diisopropylethylamine (DIPEA - 3.49 mL, 2.6 g, 20 mmol, 1.1 eq.). The reaction mixture was allowed to warm to room temperature (over 30 min), after which the reaction was complete (monitored by thin-layer chromatography (TLC)). The solvent was evaporated in vacuo to give a yellow residue which was purified by gel chromatography on a SiO2 column to give the desired product FBP-002 as a yellow oil (2.74 g, 13.8 mmol, 76%).

[0201] 1 H-NMR (400 MHz; CDCl3): δ 8.16 (m, 2H), 6.46 (dd,J1= 11.6 Hz,J2= 2.4 Hz, 1H), 6.34 (ddd,J1= 9.6 Hz,J2= 4.8 Hz,J3= 2.4 Hz, 1H), 3.21 (td,J1= 7 Hz,J2= 5.2 Hz, 2H), 1.75 (sext,J= 7.3 Hz, 2H), 1.05 (t,J= 7.4 Hz, 3H), 13 C-NMR (101 MHz; CDCl3): δ 167.7 (d,JC-F = 257 Hz), 147.7 (d,J C-F = 14 Hz), 130.1 (d,J C-F = 13 Hz), 128.8, 103.9 (d,J C-F = 25 Hz), 99.3 (d,J C-F = 27 Hz), 45.1, 22.1, 11.6. 4b -step 2

[0202]

[0203] To a solution of FBP-002 (3 g, 15 mmol, 1.0 eq.) in tetrahydrofuran (THF - 40 mL) was added butylamine (3.32 g, 4.48 mL, 45 mmol, 3 eq.) and DIPEA (3.3 g, 4.3 mL, 25.5 mmol, 1.7 eq.). The reaction mixture was stirred at 60 °C overnight. Then the solvent was evaporated and the residue was taken up in ethyl acetate (EtOAc - 150 mL), washed with saturated aqueous ammonium chloride solution (2 x 150 mL) and brine (100 mL). The combined organic layers were then dried over MgSO4, filtered and evaporated in vacuo. The obtained crude was purified by gel chromatography on a SiO2 column to obtain the desired product FBP-043 as an orange oil. (1.2 g, 4.8 mmol, 32% yield).

[0204] 1 H-NMR (400 MHz; CDCl3): δ 8.16 (m, 2H), 6.46 (dd,J1= 11.6 Hz,J2= 2.4 Hz, 1H), 6.34 (ddd,J1= 9.6 Hz,J2= 4.8 Hz,J3= 2.4 Hz, 1H), 3.21 (td,J1= 7 Hz,J2= 5.2 Hz, 2H), 1.75 (sext,J= 7.3 Hz, 2H), 1.05 (t,J= 7.4 Hz, 3H),13 C-NMR (101 MHz; CDCl3): δ 167.7 (d, J C-F = 257 Hz), 147.7 (d,J C-F = 14 Hz), 130.1 (d,J C-F = 13 Hz), 128.8, 103.9 (d,J C-F = 25 Hz), 99.3 (d,J C-F = 27 Hz), 45.1, 22.1, 11.6. 4c -stage 3

[0205]

[0206] A solution of FBP-043 (1.174 g, 4.67 mmol, 1 eq.) in THF (70 mL) was hydrogenated (P = 20 bar) in the presence of Pd / C (5%, 100 mg, 1.0 mol%) overnight. After reducing the pressure, the solution was degassed by bubbling Argon through the mixture. 1,5-Difluoro-2,4-dinitrobenzene (905 mg, 4.4 mmol, 0.95 eq.) was added at 0 °C with stirring. Maintaining this condition for 20 min, the completion of the reaction was detected by TLC (DCM / CH, 70 / 30). The Pd / C was then removed by filtration through a plug of Celite®. The crude product was purified by silica gel column chromatography (DCM / EP, 50 / 50) to give the desired product FB-005 as a deep reddish solid (1.466 g, 3.62 mmol, 77% yield).

[0207] 1H-RMN(400 MHz ; CDCl3): δ 9,30 (br, 1H), 9,14 (d,J= 8 Hz, 1H), 6,82 (d,J= 8,4 Hz, 1H), 6,53 (d,J= 13,6 Hz, 1H), 5,99 (dd,J1= 8,4 Hz,J2= 2,4 Hz, 1H), 5,95 (d,J= 2,4 Hz, 1H), 3,75 (br, 1H), 3,69 (br, 1H), 3,13 (t,J= 6 Hz, 2H), 3,06 (q,J= 6,4 Hz, 1H), 1,67-1,51 (m, 4H), 1,46 (sext,J= 7,4 Hz, 2H), 0,97 (t,J= 7,4 Hz, 3H), 0,92 (t,J= 7,4 Hz, 3H), 13 C RMN(101 MHz ; CDCl3): δ 159,9 (d,J C-F = 271 Hz), 150,5 (d,J C-F = 13 Hz), 150,3, 145,2, 128,7, 127,8, 126,9, 110,8, 103,9 (d,J C-F = 27 Hz), 101,7, 95,2, 45,3, 43,6, 43,2, 31,7, 22,6, 20,4, 14,0, 11,7. 4d -étape 4

[0208]

[0209] To a stirred solution of FB-045 (341 mg, 0.7 mmol, 0.84 mmol, 1 eq.) in acetonitrile (15 mL) was added butylamine (249 µL, 186 mg, 2.52 mmol, 3 eq.). The mixture was stirred at room temperature for 2 hours, when completion was monitored by TLC. After evaporation of the solvent, hot ethanol (10 mL) was added to the crude residue. A resulting asphalt-like material was collected by filtration and washed with hot water (30 mL), then recovered by dissolution in dichloromethane, dried over anhydrous MgSO4, and filtered. After removal of the solvent under reduced pressure and drying of the solid in vacuo, the desired product was isolated as a dark solid (354 mg; 0.67 mmol; 96%).

[0210] 1H-RMN(400 MHz ; CDCl3): δ 9,26 (s, 1H), 9,11 (s, 1H), 8,20 (t,J= 5 Hz, 1H), 6,86 (d,J= 8,4 Hz, 1H), 5,98 (dd,J1= 8,4 Hz,J2= 2,4 Hz, 1H), 5,96 (d,J= 2,4 Hz, 1H), 5,69 (s, 1H), 3,80 (t,J= 5,2 Hz, 1H), 3,67 (br, 1H), 3,13 (t,J= 7 Hz, 2H), 3,06 (q,J= 6,7 Hz, 2H), 3,01 (q,J= 6,7 Hz, 2H), 3,06 (t,J= 7 Hz, 2H), 1,67-1,51 (m, 4H), 1,45 (sext,J= 7,4 Hz, 2H), 1,33 (sext,J= 7,4 Hz, 2H), 0,97 (t,J= 7,4 Hz, 3H), 0,91 (t,J= 7,4 Hz, 3H), 0,88 (t,J= 7,4 Hz, 3H).

[0211] 13 C RMN(101 MHz ; CDCl3): δ 149,7, 149,2, 148,6, 145,4, 129,6, 128,8, 125,0, 124,5, 112,1, 101,6, 95,3, 93,1, 45,4, 43,9, 42,9, 31,8, 30,4, 22,7, 20,4, 20,2, 14,0, 13,8, 11,7. 4e -étape 5

[0212]

[0213] A solution of compound FBP-046 (340 mg, 0.74 mmol, 1 equiv.) in methanol (20 mL) was hydrogenated (20 bar) in the presence of Pd / C (5 wt%, 29 mg) and HCl (12M, 0.3 mL) for 6 hours. The mixture was then stirred in air for 16 hours. The Pd / C was removed by filtration through a plug of Celite® which was rinsed several times with methanol and dichloromethane. After removal of the solvent under reduced pressure, the resulting solid was taken up with dichloromethane (50 mL), and extracted with brine (2 x 50 mL), the organic layer was then dried over MgSO4, filtered and evaporated in vacuo to give a crude black / purple solid which was then purified on alumina oxide gel chromatography column (DCM / MeOH) and led to a deep purple solid the compound FBP-047 or compound 047 (130 mg, 0.31 mmol, 42% yield).

[0214] 1H-NMR (400 MHz; CD3OD): δ 7.72 (d,J= 9.2 Hz, 1H), 7.19 (dd,J1= 9.2 Hz,J2= 2 Hz, 1H), 6.97 (s, 1H), 6.76 (s, 1H), 6.5 (br, 1H), 4.55 (t,J= 8 Hz, 2H), 3.35-3.24 (m, 8H), 1.98 (sext,J= 7.6 Hz, 2H), 1.80-1.64 (m, 4H), 1.51 (quint,J= 7.2 Hz, 4H), 1.20 (t,J= 7.4 Hz, 3H), 1.02 (t,J= 7.4Hz, 3H), 1.01 (t,J= 7.4 Hz, 3H).

[0215] 13 CRMN(101 MHz ; CD3OD): δ 153.3, 150.8, 139.2, 138.5, 135.3, 132.6, 131.3, 130.8, 119.7, 102.7, 92.4, 89.3, 48.9, 43.4, 42.8, 30.5, 30.2, 20.3, 20.1, 19.7, 13.0, 10.1. 1 signal is masked or overlapping. 5- synthesis of compound 029

[0216]

[0217] A solution of compound FBP-025 (356 mg, 0.78 mmol, 1 equiv.) in methanol (20 mL) was hydrogenated (20 bar) in the presence of Pd / C (5 wt%, 30 mg) and HCl (12M, 0.3 mL) for 6 h. The mixture was then stirred under air overnight. The Pd / C was removed by filtration through a plug of Celite® which was rinsed several times with methanol and dichloromethane. After removal of the solvent under reduced pressure, the resulting solid was taken up with dichloromethane (50 mL), and extracted with brine (2 x 50 mL), the organic layer was then dried over MgSO4, filtered and evaporated in vacuo to give a crude black solid which was then purified on an alumina oxide gel chromatography column (Brockman activity I) (DCM / MeOH) and yielded a deep purple solid (160 mg, 39 mmol; 50%).

[0218] 1H-RMN (400 MHz ; CD3OD): δ 7.68 (d,J= 9.2 Hz, 1H), 7.16 (dd,J1= 9.2 Hz,J2= 2 Hz, 1H), 6.93 (s, 1H), 6.70 (s, 1H), 6.5 (br, 1H), 4.54 (t,J= 8 Hz, 2H), 3.32-3.19 (m, 8H), 1.89 (m, 2H), 1,79 (quint,J= 7.4 Hz, 2H), 1.73-1.58 (m, 4H), 1.49 (quint,J= 7.5 Hz, 2H), 1.1 (t,J= 7.2 Hz, 3H), 1.08 (t,J= 7.4 Hz, 3H), 1.01 (t,J= 7.4 Hz, 3H).

[0219] 13 C RMN (101 MHz ; CD3OD): δ 153.3, 150.8, 139.2, 138.5, 135.3, 132.6, 131.3, 130.8, 119.7, 102.7, 92.4, 89.3, 48.9, 43.4, 43.3, 42.6, 30.5, 30.2, 20.3, 20.2, 19.7, 13.0, 10.2. 6- synthèse du composé 392 ou 44

[0220] A solution of compound TM390 (3.08 g, 5.8 mmol, 1 equiv.) in methanol (60 mL) was hydrogenated (40 bar) in the presence of Pd / C (5 wt. %, 617 mg) and HCl (12 M, 1 mL) for 16 h. The mixture was then stirred under air for 16 h. The Pd / C was removed by filtration through a Celite® plug which was rinsed several times with methanol and dichloromethane. After removal of the solvent under reduced pressure, the resulting solid was purified on an aluminum oxide gel chromatography column (DCM / MeOH 95:5 -> 90:10) and yielded TM 392 as a deep purple solid (3% yield).

[0221] 1 H-NMR (400 MHz; CD3OD): δ 7.56 (d, 3 J= 8.97 Hz, 1H), 7.11 (dd, 3 J= 9.25 Hz, 4 J= 1.87 Hz, 1H), 6.84 (s, 1H), 6.60 (s, 1H), 6.34 (br, 1H), 4.44 (t, 3 J= 7.99 Hz, 2H), 3.76 (t, 3 J= 5.29 Hz, 2H), 3.44 (s, 3H), 3.41 (t, 3 J= 5.41 Hz, 2H), 3.27 (t, 3J= 7.09 Hz, 2H), 1.85-1.32 (mm, 16H), 1.04 (t, 3 J= 7.2 Hz, 3H), 0.92 (t, 3 J= 7.08 Hz, 3H).

[0222] Example 2 – Identification of antibiotic efflux and quantification of its efficacy

[0223] Antibiotic efflux is a phenomenon recognized as extremely serious by health authorities worldwide. It affects all bacteria but is obviously of greatest concern in a hospital setting, in intensive care, orthopedic or thoracic surgery, and in infections associated with diabetes.

[0224] Antibiotic efflux, due to its polyspecificity, has long been identified as a complement to more classic resistance mechanisms (target mutation, enzymes such as Beta-lactamase, etc.), but more recently, as intervening upstream of other mechanisms, favoring their selection.

[0225] While there are methods for identifying the main resistance mechanisms in biology laboratories, efflux is not identified and cannot be identified by a standardized method except by deductions that are not always very reliable.

[0226] It is therefore necessary to develop a method for identifying antibiotic efflux and quantifying its effectiveness. Compound 053, with its coloring and fluorescence characteristics, has proven to be an excellent tool for carrying out this type of project. Example 2-1: Staphylococcus aureus

[0227] Materials and methods:

[0228] Bacterial strains: The inventors used the following strains of Staphylococcus aureus:

[0229] - CIP 76.25, reference strain producing a basal level of NorA,

[0230] - SA1199 reference strain producing a basal level of NorA,

[0231] - SA 1199B overproduction of the NorA pump, and

[0232] - SA K1758 deleted from the NorA gene, (Kaatz et al., 2003, Antimicrob Agents Chemother. 2003 Feb;47(2):719-26).

[0233] Compound: Compound 053 (see synthesis in Example 1) is prepared in pure DMSO (Sigma) at a concentration of 20 mg / mL. It will then be diluted in milliQ water to obtain a stock solution of 1000 μg / mL.

[0234] Bacterial staining: bacteria in the exponential growth phase are incubated for 15 min in the presence of compound 053. Then the bacteria are washed twice in phosphate buffer and centrifuged, the pellets are observed with the naked eye.

[0235] Fluorescence measurement: Bacteria in the exponential growth phase are incubated for 15 min in the presence of compound 053. The optical density at 600nm is then adjusted to 0.5 and 50 µL is transferred to a black microtiter plate. The fluorescence is read in a Tecan M200 microplate reader.

[0236] The following protocol was followed:

[0237] 1. Grow the bacteria on a freshly prepared Muller Hilton-II (MH-II) agar plate. Incubate the Petri dish overnight at 37°C (Note: Incubation temperature and growth time depend on the bacteria used for the experiment).

[0238] 2. The next morning, pick one or two colonies from the overnight plate and inoculate them into an Erlenmeyer flask containing 20 ml of MH-II broth.

[0239] 3. Incubate the Erlenmeyer flask on an orbital shaking incubator at 37°C and 160 rpm for 3-4 h. Note: This step produces cells in the exponential phase, so the doubling time of the bacteria used must be considered.

[0240] 4. After incubation, transfer the cells to a centrifuge tube and centrifuge the cells at 4500 rpm for 10 minutes. Discard the supernatant. Add fresh MH-II broth to the centrifuge tube and adjust the optical density of the cells to 0.5.

[0241] 5. Transfer an aliquot (5 mL) of the cells with adjusted optical density into a new centrifuge tube (50 mL). Add 3.75 µL of the stock solution of compound 053 (1000 µg / mL) to this tube. Cap the tubes and shake them thoroughly to mix the compound. Then, keep the centrifuge tube on the table for 15 minutes at room temperature. Note: It is better to have a larger surface area to facilitate shaking. The final concentration of 053 used for the experiment is 0.75 µg / mL. Do not incubate for more than 15 minutes.

[0242] 6. After 15 minutes of contact time, centrifuge the tubes for 10-15 minutes at 4500 rpm to obtain cell pellets and discard the supernatant. Using 5 mL of phosphate buffered saline (PBS, pH 7) or potassium phosphate buffer, wash the cell pellets thoroughly (PBS, pH 7) and repeat this procedure twice. Note: Pipette repeatedly with a 5 mL or 1 mL pipette during washing. Ensure that there are no lumps during pipetting. The purpose of washing is to remove excess dye from the cell surface.

[0243] 7. The color variation in the cells is visible to the naked eye on the cell pellet after both washes.

[0244] a. Cells that overexpress the efflux pump (i.e., are resistant) will be white or off-white (default cell color).

[0245] b. Cells with normal or moderate efflux activity will be slightly pink in color.

[0246] c. Cells lacking efflux pumps or whose efflux pumps are dysfunctional will be stained dark pink.

[0247] d. Sometimes cell pellets are orange in color, indicating moderate efflux activity, this is mainly due to the inherent yellow color of the cells.

[0248] RESULTS :

[0249] Figures 1-3 show the color difference (1A) and spectrofluorometric difference (1B) observed in different reference strains (strain A, CIP 76.25), a clinical strain (strain B, SA1199), and laboratory-constructed NorA efflux pump mutants of strain B: overexpressing NorA (strain C, SA 1199B) and deleting NorA (strain D, SA K1758). Because strain C has an overexpressed efflux pump, the efflux of O53 is stronger, and the cell pellet appears white (O53 is completely eliminated by efflux). In contrast, because strain D lacks an efflux pump, the cell pellet appears dark pink. Intermediate colors can be observed for the reference strains (strain A) and clinical strains (strain B), suggesting mild to moderate activity. This is confirmed by fluorescence spectroscopy (Figures 2 and 3). It shows the fluorescence emission spectrum of compound 053 in bacterial cells after excitation at 530nm.Lamontre shows the histograms obtained by plotting the fluorescence intensity values ​​at 642 nm obtained after excitation at 530 nm.

[0250] The results obtained in colorimetry (Figures 1 to 3) clearly show that compound 053 makes it possible to visually distinguish 3 levels of coloration of the strains:

[0251] 1. A dark pink coloration corresponding to strains lacking the NorA efflux pump (SAK 1758).

[0252] 2. An absence of coloration for strains overproducing the NorA pump (SA 1199B).

[0253] 3. An intermediate pale pink coloration for strains producing basal levels of pump (SA 1199 and CIP 76.25).

[0254] It is therefore possible to identify, among the isolates, those which overproduce the NorA efflux pump, which therefore have a very high potential for resistance to antibiotics, and to differentiate them from isolates producing a basal level.

[0255] Spectrofluorimetric results () show that compound 053 is fluorescent when accumulated in bacteria and that, like the coloration, the fluorescence depends on the level of NorA pump production.

[0256] 1. The fluorescence of the overproducing strain (SA 1199B) is almost zero (Figures 2 and 3, green curve and histogram).

[0257] 2. The mutant lacking the NorA pump (SAK 1758) has high fluorescence at 670 nm (Figures 2 and 3, black curve and histogram).

[0258] 3. The two strains producing low levels of pumps (CIP 76.25, SA 1199) show intermediate levels of fluorescence (Figures 2 and 3, red and blue curves and histograms).

[0259] Unlike the colorimetric test, which does not require any special reading equipment, fluorescence requires a suitable spectrofluorometer. On the other hand, fluorescence measurement is quantitative and allows the efflux activity level of isolates to be precisely determined.

[0260] The inventors also performed a fluorescence reading by flow cytometry in order to validate the results previously obtained by spectrofluorimetry. Advantageously, flow cytometry only considers the fluorescence within the cell and not that surrounding it, thus making it possible to directly evaluate the concentration of compound 053 within the cell without the need for rinsing.

[0261] The results are consistent with those previously obtained. The fluorescence intensity measured by flow cytometry of a wild-type strain corresponding to CIP 76.25 (WT- A), a reference strain corresponding to the SA strain (Ref strain - B), a strain overproducing NorA corresponding to SA1199B (NorA overproducer - C) and a strain deleted of NorA corresponding to SA K1758 (NorA deleted - D) are shown. The cytometry results show that compound 53 accumulates moderately in the wild-type and reference strains, that it accumulates very little in the NorA-overexpressing strain and finally that it accumulates strongly in the denorA-deleted strain. The inventors also tested the impact that a fixation agent such as 1% weight / volume paraformaldehyde (PFA) or 70% cold ethanol could have on the cells treated with compound 053. The relative fluorescence intensity for each strain treated with compound 053 and with PFA (AD) or ethanol (EH) is shown.Regardless of the fixation agent used, the efflux differential between the different strains remains visible, proving the robustness of the method regardless of the fixation environment. Example 2-2: Bacillus subtilis MATERIALS AND METHODS:

[0262] Bacterial strains: the inventors used

[0263] - the reference strain Bacillus subtilis168 (DSM 402) producing a basal level of BmrA,

[0264] -Bacillus subtilisBmrA+++ overproducing the BmrA pump and

[0265] -Bacillus subtilisBmrA Δ deleted from the BmrA gene.

[0266] (seeSteinfelsEet al.Biochemistry43:7491–7502andKrügelHet al.FEMSMicrobiolLett. 2010 Dec;313(2):155-63).

[0267] The protocols used are identical to those implemented for example 2-1. RESULTS :

[0268] Figures 4 to 6 show the color difference () and spectrofluorometric difference (Figures 5 and 6) observed in the different strains of Bacillus subtilis. Strain A is the wild-type strain of B. subtilis 168 (DSM 402), strain B, BmrA+++, is a mutant overexpressing BmrA, and strain C is a BmrA deletion mutant (BmrAΔ). Since strain B overexpresses the BmrA efflux pump, compound 053 is completely efflutized from the cell, and the cell pellet appears white. In contrast, for strain C, which lacks an efflux pump, the cell pellet appears dark pink. Strain A is a normal wild-type strain expressing normal efflux activity; therefore, compound 053 is partially efflutized, and the cell pellet appears pale pink, suggesting mild to moderate activity. Similar activity is confirmed and quantified using fluorescence spectroscopy (Figures 5 and 6).

[0269] As observed on the colorimetry, it is clear that compound 053 allows to visually distinguish the BmrA mutant at 3 levels of coloration:

[0270] 1. A dark pink coloration corresponding to strains lacking the BmrA efflux pump (BmrAΔ),

[0271] 2. Absence of staining for strains overproducing the BmrA pump (BmrA +++)

[0272] 3. An intermediate pale pink coloration for strains producing basal (normal, wild-type) levels of pump.

[0273] It is therefore possible to identify, among clinical isolates, those that overproduce the efflux pump BmrA, a medium-sized ABC (ATP-binding cassette) transporter involved in multidrug resistance.

[0274] The spectrofluorimetric results (Figures 5 and 6) are consistent and quantitatively validate the results. Compound 053 is fluorescent when accumulated in bacteria and, like the coloration, the fluorescence depends on the level of production of the BmrA pump.

[0275] 1. The fluorescence of the overproducing strain (BmrA+++) is almost zero (Figures 5 and 6, curve and histogram)

[0276] 2. That of the mutant lacking the pump (BmrAΔ) is very high with a maximum at 642 nm (Figures 5 and 6, curve and histogram).

[0277] 3. The wild-type strain (DSM 402) producing low levels of pumps exhibits intermediate levels of fluorescence (Figures 5 and 6, curve and histogram).

[0278] Unlike the colorimetric test, which does not require any special reading equipment, fluorescence requires a suitable spectrofluorometer. On the other hand, fluorescence measurement is quantitative and allows the efflux activity level of isolates to be precisely determined. Example 2-3: Streptococcus pneumoniae

[0279] The inventors compared the coloration induced by compound 053 on different strains of Streptococcus pneumoniae bacteria: a wild-type strain (“WT”), a strain overexpressing PatA-PatB, an ABC transporter of Streptococcus pneumoniae allowing the transport of molecules outside the cell involved in the resistance of this pathogen to fluoroquinolone antibiotics (“OVP”), and a strain deleted from PatA-PatB (“DEL”). MATERIALS AND METHODS:

[0280] Bacterial strains: the inventors used

[0281] -WT: the reference strain Streptococcus pneumoniae producing a basal level of PatA-PatB

[0282] -OVP: strain overproducing PatA-PatB

[0283] -DEL: strain deleted from the gene coding for PatA-PatB

[0284] The protocols used are identical to those implemented for example 2-1. RESULTS :

[0285] Figures 9 and 10 show the color difference () and spectrofluorometric difference () observed on the different strains of Streptococcus pneumoniae.

[0286] Since the OVP strain overexpresses the PatA-PatB transporter, compound 053 is strongly effluxed from the cell, and the cell pellet appears white. In contrast, for the WT strain and the DEL strain, which lacks the PatA-PatB transporter, the cell pellet appears dark pink. Similar activity is confirmed and quantified using fluorescence spectroscopy ().

[0287] Compound 053 therefore makes it possible to qualitatively and quantitatively distinguish a strain overexpressing an ABC transporter PatA-PatB from a strain not overexpressing or not expressing this transporter at all. Example 2-4: Escherichia coli

[0288] a) Compounds 392 and 29.

[0289] The inventors tested the use of compound 392 and compound 29 on different strains of E. coli exhibiting varying levels of expression of the AcrAB efflux pump. MATERIALS AND METHODS:

[0290] The experimental protocol is the same as that described in the previous examples except for the bacterial strains used. Briefly, compounds 29 and 392 (1 μg / mL) were added to 5 ml of a cell suspension of different E. coli strains (OD = 1.5), mixed by tilting and left to stand on the table at room temperature for 15 min. Then, the cells were centrifuged at 3,500 rpm for 10 min and rinsed with potassium phosphate buffer (PBP). A single washing step of the cell pellet was performed. Bacterial strains:

[0291] StrainDescriptionAbbreviationEC (ATCC 11775)Reference bacterium with normal efflux activityEC (ref)AG100Wild-type bacterium (parent)WTAG100ABacterium with acrABΔ acrABA deletionG102Bacterium overexpressingacrABacrAB+++ RESULTS :

[0292] Figures 11 to 16 show the color difference (Figures 11 and 14) and the spectrofluorimetric difference (Figures 12, 13, 15 and 16) observed on the different strains of Escherichia coli. Strain EC (ref) is the reference strain (ATCC 11775) showing normal efflux, strain AG100 is the wild-type strain of E. coli (Wild) also showing normal efflux, strain AG102 is an AcrAB overexpressing mutant (acrAB+++) showing strong efflux and strain AG100A (Δ acrAB) is an acrAB deletion mutant showing weak efflux.

[0293] As seen in Figures 11 and 14, bacteria with normal efflux (EC and AG100) are marked with a very pale pink color, while the strain with a deletion of the gene encoding the AcrAB pump (AG100A) has a dark pink color. In contrast, the strain with overexpression of AcrAB (AG102) is not marked. The same difference in efflux activity between the different strains is confirmed and even more marked by fluorescence spectroscopy (Figures 12, 13, 15 and 16).

[0294] b) Compound 053

[0295] The inventors also tested compound 053 (1 µg / mL) on the same Escherichia coli strains with varying levels of expression of the AcrAB efflux pump. The protocol was slightly modified to introduce a step of pre-treating the strains with Carbonyl Cyanide m-Chlorophenylhydrazone (CCCP). CCCP is a chemical inhibitor of oxidative phosphorylation. It interferes with the transmembrane electrochemical gradient and the proton motive force and consequently reduces ATP production. CCCP has the effect of reducing the efficiency of efflux pumps, which allows for better perception of the differences in labeling between the different strains.

[0296] Chemical structure of CCCP MATERIALS AND METHODS:

[0297] The experimental protocol is the same as that described in the examples except that the cells are treated for 1 h with CCCP (5 µg / mL) in phosphate buffer (PPB). After treatment with CCP, the entire experiment is carried out in PPB instead of MH-II broth from step 4. RESULTS :

[0298] As seen in the figure, it is visually possible to distinguish strains with normal efflux (EC, AG100) or no efflux (AG100A) from the strain overexpressing AcrAB (AG102). Fluorescence spectroscopy analysis (Figures 18 and 19) confirms this observation.

Claims

Compound of the following formula I: (I)where X - is a halogen atom, or an acceptable counterion, especially Cl, where R1 and R2 are either jointly -CH 3 , or-C 4 H 9 - either a C alkyl 1 -C 4 , such that if R1 is a C alkyl n+ i , R2 is C alkyl n , and conversely, n being an integer varying from 1 to 3, i being an integer varying from 1 to 3 and or n+i varying from 1 to 4;- either R1 is -C 4 H 7 and R2 is C 8 H 17 ,and where R3 is a -CH 3 , or a C alkyl 2 -C 8 , said C alkyl 2 -C 8 being possiblement substitué par un ou plusieurs hétéroatomes ;ou un sel ou un solvate de ce composé de forme I, ou une forme protonée de celui-ci. A compound according to claim 1:where R1 and R2 are either together -CH 3 ,- either a C alkyl 1 -C 4 , such that if R1 is a C alkyl n+i , R2 is C alkyl n, and conversely, n being an integer varying from 1 to 3, i being an integer varying from 1 to 3 and or n+i varying from 1 to 4;andwhere R3 is a -CH 3 , or a C alkyl 2 -C 8 , said C alkyl 2 -C 8 being possiblement substitué par un ou plusieurs hétéroatomes ;ou un sel ou un solvate de ce composé de forme I, ou une forme protonée de celui-ci. A compound according to claim 1 or claim 2, wherein R1 and R2 are each C 1 -C 2 alkyl. 2 -C 4 , such that:- if R1 is a C alkyl n+ i , R2 is C alkyl n , or- if R2 is C alkyl n+ i , R1 is C alkyl n ,n varying from 1 to 3, i being an integer varying from 1 to 3 and where n+i varies from 1 to 4. A compound according to any one of claims 1 to 3, where R3 is a C2-C4 alkoxy group, a dimethylamineethyl or methylaminexethyl group. A compound according to any one of claims 1 to 4, said compound being selected from the group of compounds of formula I, where R1, R2 and R3 are together as indicated in each row of the following table:compoundR1R2R3methylmethylpropylmethylethylpropylethylmethylpropylethylpropylpropylpropylpropylethylpropylbutylpropylbutylpropylpropylmethylmethylbutylmethylethylbutylethylmethylbutylethylmethylbutylethylpropylbutylpropylethylbutylbutylbutyl#47butylpropylbutylmethylmethylmethoxyethylmethylethylmethoxyethylethylmethylmethoxyethylpropylmethoxyethylpropylbutylmethoxyethyl#53butylpropylmethoxyethyl#52butylpropyloctyl#392butyloctylmethoxyethyl#29butylbutylpropyl A compound according to any one of claims 1 to 5, said compound being selected from the compounds of formulae 47, 52, 53, 392 and 29 below: (47), (52), (53), (392), and (29). Use of a compound according to any one of claims 1 to 6, for evaluating or measuring the efflux of said compound by a bacterium. Use according to claim 7, for assessing or measuring efflux by a Gram-positive bacterium. Use according to claim 7, for assessing or measuring efflux by a Gram-negative bacterium. Kit for detecting or measuring bacterial efflux, comprising- a compound according to any one of claims 1 to 6, and- at least one control bacterium. Detection kit according to claim 10, further comprising a protonophore notably chosen from 2,4-dinitrophenol, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), C4R1, Ellipticine, 10-[2-(3-hydroxy-6-oxo-xanthen-9-yl)benzoyl]oxydecyl-triphenyl-phosphonium bromide and 2-(2-Hydroxyaryl)hexylphosphonium bromide. Use of a compound according to any one of claims 1 to 6, for evaluating the resistance of a bacterium to a bacteriostatic or bactericidal compound. A method for evaluating resistance due to an efflux mechanism of a bacterium to a bacteriostatic or bactericidal compound, comprising:- culturing bacteria in a suitable culture medium, to obtain a culture of bacteria,- contacting the culture of bacteria with a compound as defined in any one of claims 1 to 6, to obtain a culture of treated bacteria,- washing the culture of treated bacteria, and precipitating the bacteria contained in the culture of treated bacteria to obtain a pellet of bacteria,- observing the coloration of the pellet of bacteria, such that- if the pellet of bacteria has the color of a pellet of bacteria from the culture of untreated bacteria, said bacterium is resistant to said bacteriostatic or bactericidal compound, by efflux of said bacteriostatic or bactericidal compound,and- if the pellet of bacteria has a color different from the color of a pellet of bacteria from the culture of untreated bacteria, said bacterium is not resistant to said bacteriostatic or bactericidal compound by efflux of said bacteriostatic or bactericidal compound., The method of claim 13, said method further comprising a step of incubating the bacteria culture with a protonophore.